Drug intelligence / Profile preview

LP-DF003

Development stage: Unknown
Lead developer: Mireca Medicines
Modality: Small Molecules
Administration: Ophthalmic

Overview

LP-DF003 is a small molecule drug developed by Mireca Medicines GmbH (formerly 2-BBB Medicines BV) for the treatment of inherited retina degeneration, including retinitis pigmentosa. The drug functions by down-regulating overexpressed cyclic guanosine monophosphate (cGMP). It has received EMA Orphan Drug Status for retinitis pigmentosa and has completed pharmacological proof-of-concept studies.

Beyond the preview

Go deeper on LP-DF003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LP-DF003.

Explore the full profile